{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:35:13Z","timestamp":1778819713978,"version":"3.51.4"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["EEQ\/ 2021\/000955"],"award-info":[{"award-number":["EEQ\/ 2021\/000955"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.arr.2024.102482","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:42:42Z","timestamp":1725378162000},"page":"102482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Imidazoline receptors as a new therapeutic target in Huntington\u2019s disease: A preclinical overview"],"prefix":"10.1016","volume":"101","author":[{"given":"Sakshi","family":"Jari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandini","family":"Ratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manasi","family":"Tadas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj","family":"Katariya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Kale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind","family":"Umekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brijesh","family":"Taksande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2024.102482_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2021.183663","article-title":"Mitochondrial membranes modify mutant huntingtin aggregation","volume":"1863","author":"Adegbuyiro","year":"2021","journal-title":"Biochim. Et. Biophys. Acta (BBA) Biomembr."},{"key":"10.1016\/j.arr.2024.102482_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mito.2023.05.007","article-title":"Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease, and Parkinson\u2019s disease, Huntington\u2019s disease and Amyotrophic Lateral Sclerosis -an updated review","volume":"71","author":"Alqahtani","year":"2023","journal-title":"Mitochondrion"},{"key":"10.1016\/j.arr.2024.102482_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1755-5949.2010.00134.x","article-title":"Dopamine and glutamate in Huntington\u2019s disease: a balancing act","volume":"16","author":"Andr\u00e9","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.arr.2024.102482_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","article-title":"Protein aggregates in Huntington\u2019s disease","volume":"238","author":"Arrasate","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2024.102482_bib5","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/00207450902787165","article-title":"Protection in glutamate-induced neurotoxicity by imidazoline receptor agonist moxonidine","volume":"119","author":"Bakuridze","year":"2009","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.arr.2024.102482_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11064-018-02712-1","article-title":"Therapeutic effect of agmatine on neurological disease: focus on ion channels and receptors","volume":"44","author":"Barua","year":"2019","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.arr.2024.102482_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4103\/0253-7613.165196","article-title":"The imidazoline receptors and ligands in pain modulation","volume":"47","author":"Bektas","year":"2015","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112692","article-title":"Neuroprotective action of agmatine in rotenone-induced model of Parkinson\u2019s disease: role of BDNF\/cREB and ERK pathway","volume":"392","author":"Bilge","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.arr.2024.102482_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/pr.118.016311","article-title":"Imidazoline receptor system: the past, the present, and the future","volume":"72","author":"Bousquet","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.arr.2024.102482_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/pr.118.016311","article-title":"Imidazoline receptor system: the past, the present, and the future","volume":"72","author":"Bousquet","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.arr.2024.102482_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2016.00317","article-title":"Corticostriatal dysfunction in Huntington\u2019s disease: the basics","volume":"10","author":"Bunner","year":"2016","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.arr.2024.102482_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2013.00114","article-title":"Dopamine imbalance in Huntington\u2019s disease: a mechanism for the lack of behavioral flexibility","volume":"7","author":"Chen","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.arr.2024.102482_bib13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0891-5849(01)00819-X","article-title":"Imidazoline drugs stabilize lysosomes and inhibit oxidative cytotoxicity in astrocytes","volume":"32","author":"Choi","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.arr.2024.102482_bib14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0891-5849(02)01041-9","article-title":"Protective effects of rilmenidine and AGN 192403 on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes","volume":"33","author":"Choi","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.arr.2024.102482_bib15","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.bbrc.2018.08.086","article-title":"Protective effect of the imidazoline I2 receptor agonist 2-BFI on oxidative cytotoxicity in astrocytes","volume":"503","author":"Choi","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.arr.2024.102482_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1471-4159.2010.07085.x","article-title":"Agmatine effects on mitochondrial membrane potential andNF-\u03baB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells","volume":"116","author":"Condello","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.arr.2024.102482_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02246578","article-title":"The\u03b1 2 antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type","volume":"123","author":"Coull","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.arr.2024.102482_bib18","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s13311-020-00891-w","article-title":"Therapeutic update on Huntington\u2019s disease: symptomatic treatments and emerging disease-modifying therapies","volume":"17","author":"Dash","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.arr.2024.102482_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tips.2008.06.005","article-title":"Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders","volume":"29","author":"Di Filippo","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.arr.2024.102482_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/jnsbm.JNSBM_239_17","article-title":"Neuroprotective effect of agmatine in mouse spinal cord injury model: modulation by imidazoline receptors","volume":"9","author":"Dixit","year":"2018","journal-title":"J. Nat. Sci. Biol. Med."},{"key":"10.1016\/j.arr.2024.102482_bib21","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S2215-0366(16)30144-4","article-title":"Changes in mental state and behaviour in Huntington\u2019s disease","volume":"3","author":"Eddy","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.arr.2024.102482_bib22","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/1853\/1\/012066","article-title":"Multi target-directed imidazole derivatives for neurodegenerative diseases","volume":"1853","author":"Eliewi","year":"2021","journal-title":"J. Phys. Conf. Ser."},{"key":"10.1016\/j.arr.2024.102482_bib23","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2019.33.1_supplement.806.19","article-title":"A new family of imidazoline I2 receptor ligands improves behavior and cognition in SAMP8 mice","volume":"33","author":"Escolano","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.arr.2024.102482_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0269881112450785","article-title":"Chronic treatment with selective I 2 -imidazoline receptor ligands decreases the content of pro-apoptotic markers in rat brain","volume":"27","author":"Garau","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1749-6632.1999.tb09388.x","article-title":"Imidazoline receptors and human brain disorders a","volume":"881","author":"Garc\u00eda-Sevilla","year":"1999","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.arr.2024.102482_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0304-3940(98)00265-1","article-title":"Imidazoline receptor proteins in brains of patients with Alzheimer\u2019s disease","volume":"247","author":"Garc\u0131\u0301a-Sevilla","year":"1998","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2024.102482_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/cns.12826","article-title":"Alteration of <scp>GABA<\/scp> ergic neurotransmission in Huntington\u2019s disease","volume":"24","author":"Garret","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.arr.2024.102482_bib28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bbrc.2006.01.136","article-title":"Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction","volume":"342","author":"Goswami","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.arr.2024.102482_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.brainresbull.2014.02.007","article-title":"Pharmacological benefit of I1-imidazoline receptors activation and nuclear factor kappa-B (NF-\u03baB) modulation in experimental Huntington\u2019s disease","volume":"102","author":"Gupta","year":"2014","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.arr.2024.102482_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.brainresbull.2014.02.007","article-title":"Pharmacological benefit of I1-imidazoline receptors activation and nuclear factor kappa-B (NF-\u03baB) modulation in experimental Huntington\u2019s disease","volume":"102","author":"Gupta","year":"2014","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.arr.2024.102482_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.brainresbull.2014.02.007","article-title":"Pharmacological benefit of I1-imidazoline receptors activation and nuclear factor kappa-B (NF-\u03baB) modulation in experimental Huntington\u2019s disease","volume":"102","author":"Gupta","year":"2014","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.arr.2024.102482_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.brainresbull.2014.02.007","article-title":"Pharmacological benefit of I1-imidazoline receptors activation and nuclear factor kappa-B (NF-\u03baB) modulation in experimental Huntington\u2019s disease","volume":"102","author":"Gupta","year":"2014","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.arr.2024.102482_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2013.12.003","article-title":"Pharmacological modulation of I1-imidazoline and \u03b12-adrenoceptors in sub acute brain ischemia induced vascular dementia","volume":"723","author":"Gupta","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib34","article-title":"Fast, non-competitive and reversible inhibition of NMDA-activated currents by 2-BFI confers neuroprotection","volume":"8","author":"Han","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2024.102482_bib35","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/mds.25422","article-title":"Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington\u2019s disease","volume":"28","author":"Hart","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2024.102482_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152506775268758","article-title":"Imidazoline receptors, novel agents and therapeutic potential","volume":"4","author":"Head","year":"2006","journal-title":"Cardiovasc Hematol. Agents Med. Chem."},{"key":"10.1016\/j.arr.2024.102482_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/187152506775268758","article-title":"Imidazoline receptors, novel agents and therapeutic potential","volume":"4","author":"Head","year":"2006","journal-title":"Cardiovasc Hematol. Agents Med. Chem."},{"key":"10.1016\/j.arr.2024.102482_bib38","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/01.WNL.0000098878.47789.BD","article-title":"Profile of cognitive progression in early Huntington\u2019s disease","volume":"61","author":"Ho","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2024.102482_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1570159X16666180302115032","article-title":"Insight into the emerging role of striatal neurotransmitters in the pathophysiology of Parkinson\u2019s disease and Huntington\u2019s disease: a review","volume":"17","author":"Jamwal","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2014.00073","article-title":"The ubiquitin proteasome system in glia and its role in neurodegenerative diseases","volume":"7","author":"Jansen","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.arr.2024.102482_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.freeradbiomed.2013.04.016","article-title":"PGC-1\u03b1, mitochondrial dysfunction, and Huntington\u2019s disease","volume":"62","author":"Johri","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.arr.2024.102482_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.147045","article-title":"Agmatine modulates anxiety and depression-like behaviour in diabetic insulin-resistant rats","volume":"1747","author":"Kale","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.arr.2024.102482_bib43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuro.2024.03.002","article-title":"Agmatine mitigates behavioral abnormalities and neurochemical dysregulation associated with 3-Nitropropionic acid-induced Huntington\u2019s disease in rats","volume":"102","author":"Katariya","year":"2024","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.arr.2024.102482_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102269","article-title":"Agmatine as a novel intervention for Alzheimer\u2019s disease: pathological insights and cognitive benefits","volume":"96","author":"Katariya","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2024.102482_bib45","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.nucmedbio.2014.12.014","article-title":"In vivo evaluation of a new 18F-labeled PET ligand, [18F]FEBU, for the imaging of I2-imidazoline receptors","volume":"42","author":"Kawamura","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.arr.2024.102482_bib46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0269881116652579","article-title":"Inhibitory effects of imidazoline receptor ligands on basal and kainic acid-induced neurotoxic signalling in mice","volume":"30","author":"Keller","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.brainres.2009.04.044","article-title":"Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site","volume":"1279","author":"Kimura","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.arr.2024.102482_bib48","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0006-8993(95)00083-3","article-title":"Quantitative autoradiographic localization in rat brain of \u03b12-adrenergic and non-adrenergic I-receptor binding sites labelled by [3H]rilmenidine","volume":"675","author":"King","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.arr.2024.102482_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172976","article-title":"Agmatine reverses memory deficits induced by A\u03b21\u201342 peptide in mice: a key role of imidazoline receptors","volume":"196","author":"Kotagale","year":"2020","journal-title":"Pharm. Biochem. Behav."},{"key":"10.1016\/j.arr.2024.102482_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172976","article-title":"Agmatine reverses memory deficits induced by A\u03b21\u201342 peptide in mice: a key role of imidazoline receptors","volume":"196","author":"Kotagale","year":"2020","journal-title":"Pharm. Biochem. Behav."},{"key":"10.1016\/j.arr.2024.102482_bib51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neuro.2019.05.001","article-title":"Neuroprotective offerings by agmatine","volume":"73","author":"Kotagale","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.arr.2024.102482_bib52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/genes12060813","article-title":"Interleukins and interleukin receptors evolutionary history and origin in relation to CD4+ T cell evolution","volume":"12","author":"Kubick","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.arr.2024.102482_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/584758","article-title":"Hypoxia inducible factor pathway and physiological adaptation: a cell survival pathway?","volume":"2015","author":"Kumar","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.arr.2024.102482_bib54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pharmthera.2017.03.009","article-title":"Imidazoline I 2 receptors: an update","volume":"178","author":"Li","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.arr.2024.102482_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pharmthera.2017.03.009","article-title":"Imidazoline I 2 receptors: an update","volume":"178","author":"Li","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.arr.2024.102482_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2011.02.038","article-title":"Imidazoline I2 receptors: target for new analgesics?","volume":"658","author":"Li","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib57","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.pharep.2014.06.003","article-title":"Antiproliferative effect induced by novel imidazoline S43126 in PC12 cells is mediated by ROS, stress activated MAPKs and caspases","volume":"66","author":"McLean","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.arr.2024.102482_bib58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.expneurol.2010.11.003","article-title":"Autophagy and misfolded proteins in neurodegeneration","volume":"238","author":"Metcalf","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2024.102482_bib59","first-page":"419","article-title":"Neurotoxicity of CI-980, a novel mitotic inhibitor","volume":"3","author":"Meyers","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.arr.2024.102482_bib60","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/S0028-3908(00)00085-X","article-title":"Imidazoline-induced neuroprotective effects result from blockade of NMDA receptor channels in neuronal cultures","volume":"39","author":"Milhaud","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2024.102482_bib61","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/S0028-3908(00)00085-X","article-title":"Imidazoline-induced neuroprotective effects result from blockade of NMDA receptor channels in neuronal cultures","volume":"39","author":"Milhaud","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2024.102482_bib62","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/bph.15312","article-title":"Imidazoline ligand BU224 reverses cognitive deficits, reduces microgliosis and enhances synaptic connectivity in a mouse model of Alzheimer\u2019s disease","volume":"178","author":"Mirzaei","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib63","series-title":"in: Neuroprotection","article-title":"Current Therapeutic Approaches from Imidazoline and Opioid Receptors Modulators in Neuroprotection","author":"Mititelu-Tartau","year":"2019"},{"key":"10.1016\/j.arr.2024.102482_bib64","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.3390\/ijms23137320","article-title":"I2-imidazoline ligand CR4056 improves memory, increases apoe expression and reduces BBB leakage in 5xFAD mice","volume":"23","author":"Mota","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102482_bib65","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.3390\/ijms23137320","article-title":"I2-imidazoline ligand CR4056 improves memory, increases ApoE expression and reduces BBB leakage in 5xFAD mice","volume":"23","author":"Mota","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102482_bib66","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1139\/cjpp-2018-0021","article-title":"Imidazolines increase the levels of the autophagosomal marker LC3-II in macrophage-like RAW264.7 cells","volume":"96","author":"Nakagawa","year":"2018","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib67","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1586\/ern.09.68","article-title":"Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson\u2019s disease","volume":"9","author":"Naoi","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.arr.2024.102482_bib68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1755-5922.2011.00269.x","article-title":"Imidazoline antihypertensive drugs: selective I 1 -imidazoline receptors activation","volume":"30","author":"Nikolic","year":"2012","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.arr.2024.102482_bib69","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/sj.bjp.0702679","article-title":"Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor","volume":"127","author":"Olmos","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib70","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1749-6632.1999.tb09354.x","article-title":"Pharmacologic and molecular discrimination of I 2 -imidazoline receptor subtypes a","volume":"881","author":"OLMOS","year":"1999","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.arr.2024.102482_bib71","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.2174\/0929867327666200705225821","article-title":"Transcriptional dysregulation in Huntington\u2019s disease: the role in pathogenesis and potency for pharmacological targeting","volume":"28","author":"Pogoda","year":"2021","journal-title":"Curr. Med .Chem."},{"key":"10.1016\/j.arr.2024.102482_bib72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.brainresbull.2009.07.010","article-title":"Role of mitochondrial dysfunction in the pathogenesis of Huntington\u2019s disease","volume":"80","author":"Quintanilla","year":"2009","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.arr.2024.102482_bib73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev.pa.36.040196.002455","article-title":"Imidazoline receptors and their endogenous ligands","volume":"36","author":"Regunathan","year":"1996","journal-title":"Annu Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.arr.2024.102482_bib74","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","article-title":"Genetics and neuropathology of Huntington's disease","volume":"98","author":"Reiner","year":"2011","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.arr.2024.102482_bib75","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1093\/ajh\/5.4.51S","article-title":"Imidazole receptors and clonidine-displacing substance in relationship to control of blood pressure, neuroprotection, and adrenomedullary secretion","volume":"5","author":"Reis","year":"1992","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.arr.2024.102482_bib76","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1016\/0002-9149(94)90038-8","article-title":"Protection of focal ischemic infarction by rilmenidine in the animal: evidence that interactions with central imidazoline receptors may be neuroprotective","volume":"74","author":"Reis","year":"1994","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.arr.2024.102482_bib77","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1016\/0014-2999(96)00196-3","article-title":"Imidazoline binding sites in Huntington\u2019s and Parkinson\u2019s disease putamen","volume":"301","author":"Reynolds","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib78","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/hmg\/ddq093","article-title":"Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington\u2019s disease","volume":"19","author":"Rose","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.arr.2024.102482_bib79","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0033-3182(00)71170-4","article-title":"Neuropsychiatry of Huntington\u2019s disease and other basal Ganglia disorders","volume":"41","author":"Rosenblatt","year":"2000","journal-title":"Psychosomatics"},{"issue":"18","key":"10.1016\/j.arr.2024.102482_bib80","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1042\/BCJ20180503","article-title":"Isoproterenol-induced beta-2 adrenergic receptor activation negatively regulates interleukin-2 signalling","volume":"475","author":"Ruiz-Medina","year":"2018","journal-title":"Biochem J"},{"key":"10.1016\/j.arr.2024.102482_bib81","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1080\/1028415X.2021.1913319","article-title":"Naringenin mitigates behavioral alterations and provides neuroprotection against 3-nitropropinoic acid-induced Huntington\u2019s disease like symptoms in rats","volume":"25","author":"Salman","year":"2022","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.arr.2024.102482_bib82","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl. Med. Commun."},{"key":"10.1016\/j.arr.2024.102482_bib83","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12272-024-01499-w","article-title":"Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington\u2019s disease","volume":"47","author":"Shafie","year":"2024","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.arr.2024.102482_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0197-0186(02)00196-1","article-title":"Neurodegenerative disorders of protein aggregation","volume":"43","author":"Shastry","year":"2003","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.arr.2024.102482_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.731483","article-title":"Liraglutide improves cognitive and neuronal function in 3-NP rat model of Huntington\u2019s disease.","volume":"12","author":"Shawki","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.arr.2024.102482_bib86","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuropharm.2009.06.035","article-title":"Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine","volume":"57","author":"Taksande","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2024.102482_bib87","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuropharm.2009.06.035","article-title":"Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine","volume":"57","author":"Taksande","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2024.102482_bib88","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2018.09.022","article-title":"Huntington disease: a quarter century of progress since the gene discovery","volume":"396","author":"Testa","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.arr.2024.102482_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neures.2017.10.010","article-title":"The protective effect of 2-(2-benzonfu-ranyl)-2-imidazoline against oxygen-glucose deprivation in cultured rat cortical astrocytes","volume":"133","author":"Tian","year":"2018","journal-title":"Neurosci Res"},{"key":"10.1016\/j.arr.2024.102482_bib90","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/17460441.2023.2201493","article-title":"Animal models of Huntington\u2019s disease and their applicability to novel drug discovery and development","volume":"18","author":"Upadhayay","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.arr.2024.102482_bib91","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3390\/ijms23031128","article-title":"Do We have viable protective strategies against Anesthesia-induced developmental neurotoxicity?","volume":"23","author":"Useinovic","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2024.102482_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577380","article-title":"Inflammation in Huntington\u2019s disease: a few new twists on an old tale","volume":"348","author":"Valad\u00e3o","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.arr.2024.102482_bib93","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.brainres.2008.11.059","article-title":"Idazoxan attenuates spinal cord injury by enhanced astrocytic activation and reduced microglial activation in rat experimental autoimmune encephalomyelitis","volume":"1253","author":"Wang","year":"2009","journal-title":"Brain Res."},{"issue":"10","key":"10.1016\/j.arr.2024.102482_bib94","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2279","article-title":"Muscle Histology Characterization Using H&E Staining and Muscle Fiber Type Classification Using Immunofluorescence Staining","volume":"7","author":"Wang","year":"2017","journal-title":"Bio Protoc"},{"key":"10.1016\/j.arr.2024.102482_bib95","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-022-00524-0","article-title":"Solving neurodegeneration: common mechanisms and strategies for new treatments","volume":"17","author":"Wareham","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2024.102482_bib96","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nchembio.79","article-title":"Novel targets for Huntington\u2019s disease in an mTOR-independent autophagy pathway","volume":"4","author":"Williams","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.arr.2024.102482_bib97","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.brainresbull.2021.06.016","article-title":"The 2-(2-benzofuranyl)-2-imidazoline provides neuroprotection against focal cerebral ischemia-reperfusion injury in diabetic rats: influence of microglia and possible mechanisms of action","volume":"174","author":"Xi","year":"2021","journal-title":"Brain Res Bull."},{"key":"10.1016\/j.arr.2024.102482_bib98","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41401-020-00558-4","article-title":"Ginsenoside Rg1 exerts neuroprotective effects in 3-nitropronpionic acid-induced mouse model of Huntington\u2019s disease via suppressing MAPKs and NF-\u03baB pathways in the striatum","volume":"42","author":"Yang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.arr.2024.102482_bib99","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.12.041","article-title":"2-(2-Benzofuranyl)-2-Imidazoline mediates neuroprotection by regulating the neurovascular unit integrity in a rat model of focal cerebral Ischemia","volume":"27","author":"Zhang","year":"2018","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.arr.2024.102482_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146695","article-title":"Moxonidine inhibits excitatory inputs to airway vagal preganglionic neurons via activation of both \u03b12-adrenoceptors and imidazoline I1 receptors","volume":"1732","author":"Zhou","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.arr.2024.102482_bib101","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s11064-014-1502-0","article-title":"Brain protection conferred by long-term administration of 2-(2-Benzofuranyl)-2-imidazoline against experimental autoimmune encephalomyelitis","volume":"40","author":"Zhu","year":"2015","journal-title":"Neurochem. Res."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163724003003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163724003003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T02:54:52Z","timestamp":1730516092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163724003003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":101,"alternative-id":["S1568163724003003"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2024.102482","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imidazoline receptors as a new therapeutic target in Huntington\u2019s disease: A preclinical overview","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2024.102482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102482"}}